Medical Rhinoplasty: Evaluation of the Efficacy of Hyaluronic Acid in the Treatment of Internal Nasal Valves. (Rhinomedifon)

Functional Medical Rhinoplasty: Objective Evaluation of the Efficacy of Hyaluronic Acid Injections in the Septo-triangular Angle in the Treatment of Internal Nasal Valves

Nasal obstruction is a possible complication of rhinoplasty surgery. Several causes can explain it: deviation of the nasal septum, appearance of mucosal flanges inside the nasal cavity, but also collapse of the internal valve by its fragility. All surgeons performing rhinoplasty or rhinoseptoplasty are unfortunately confronted with this. Thus, when a rhinoplasty patient complains of postoperative nasal obstruction, the surgeon routinely performs several explorations:

• Inspection of the nasal cavity with a nasofibroscope
• Study of the nasal respiratory flows with a rhinomanometer The results of these 2 explorations allow to determine the cause of the obstruction and if it is explained or not by a collapse of the internal valve.

When internal valve collapse is the cause of postoperative nasal obstruction, few alternatives exist to treat this problem. Revision surgery under general anesthesia is usually necessary, with placement of a cartilage graft (= spreader graft) in the septo-triangular angle to reopen and support it. An alternative treatment is the injection of hyaluronic acid into the septo-triangular angle instead of the cartilage graft placed in the operating room. This option has several advantages: it is performed during the consultation, no general anesthesia is required, the procedure is quick, the cost is much lower, the patient's nasal breathing improves immediately, and the post-procedure follow-up is simple. The aim of our study is therefore to objectively analyze the modification of nasal biomechanics after injection of hyaluronic acid in the septo-triangular angle in patients with internal nasal valve (post (septo)-rhinoplasty). This objective evaluation will be performed with a rhinomanometer, before and after injection. This is a simple, non-invasive measuring device that allows the measurement of the main physical variables governing the biomechanics of the fluids inside the nasal cavity, such as pressure, flow and therefore nasal resistance. The objective proof of such an efficiency will allow a better management of the patients, to universalize the practices, to decrease the cost of the treatment and eventually to bring arguments to the health authorities for the reimbursement of such procedures.

Study Overview

• Status: Withdrawn
• Conditions: Nasal Obstruction
• Intervention / Treatment: Diagnostic test: Rhinomanometry

• Study Type: Observational

Contacts and Locations

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: N/A

• Sampling Method: Non-Probability Sample

Study Population

Adults Patients presenting a nasal obstruction post (septo)rhinoplasty, caused by an internal valve syndrome, which must benefit from an injection of hyaluronic acid will be included (in the absence of criteria of non-inclusion and after collection of the non-opposition of the patient).

Description

Inclusion Criteria:

• Major patients of all ages:
• Previous rhinoplasty or rhinoseptoplasty surgery
• Carrier of a nasal obstruction by collapsed internal valve
• Requiring an injection of hyaluronic acid in the septo-triangular angle
• Nasal obstruction by internal valve collapse is defined by (all elements must be present):
• Patient complaining of nasal obstruction (uni or bilateral)
• Collapse of the internal valve during normal nasal inspiratory effort on physical examination
• Improvement of the collapse and therefore of the nasal obstruction at the Bachmann maneuver during the physical examination
• Rhinomanometric internal valve criteria: area under the curve value on the flow/pressure diagram at the inspiratory phase ABOVE the diagnostic threshold (>18 622)
• Patients who did not object to their participation in the study

Exclusion Criteria:

1. Patients unable to complete questionnaires and visual scales

2. Patients with another cause of associated nasal obstruction:

   • Persistent septal deviation
   • Mucosal synechiae
   • Septal perforation
   • Turbinate hypertrophy
   • Inspiratory collapse of the external valve
   • Allergic rhinitis
   • Vasomotor rhinitis
   • Nasosinus polyposis
   • Nasal cavity or cavum tumors

Study Plan

How is the study designed?

Design Details

• Observational Models: Cohort
• Time Perspectives: Prospective

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Area under the curve of the "inspiratory open loop" on the flow-pressure diagram	Value of the area of the "inspiratory open loop" (on the flow/pressure diagram produced by the rhinomanometer, in the inspiratory phase), and position of this value in relation to the diagnostic threshold of internal valve syndrome.	change between Day 0 before injection and Month 1 after injection

Collaborators and Investigators

• Sponsor: Hospices Civils de Lyon
• Investigators: Principal Investigator: Alain-Ali MOJALLAL, MD, Service de chirurgie plastique, esthétique et reconstructrice

Study record dates

Study Major Dates

• Study Start (Actual): April 1, 2023
• Primary Completion (Actual): December 1, 2023
• Study Completion (Actual): December 1, 2023

Study Registration Dates

• First Submitted: October 27, 2021
• First Submitted That Met QC Criteria: November 24, 2021
• First Posted (Actual): November 26, 2021

Study Record Updates

• Last Update Posted (Actual): January 25, 2024
• Last Update Submitted That Met QC Criteria: January 24, 2024
• Last Verified: January 1, 2024

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Respiratory Tract Diseases; Respiration Disorders; Otorhinolaryngologic Diseases; Nose Diseases; Respiratory Insufficiency; Airway Obstruction; Nasal Obstruction
• Other Study ID Numbers: 69HCL21_0929

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No